After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial. The ...

Founders of two Philadelphia-area real estate firms cracked Forbes' list of the world's billionaires while one local resident ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 2.92% to $485.89 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to ...

In a report released today, Chris Quintero from Morgan Stanley maintained a Buy rating on Vertex (VERX – Research Report), with a price target ...

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vertex Pharmaceuticals was filed on April 1, 2025 so you should expect the ...